Back to results
US 2026/0216308 A1Published application
Methods of treating and preventing clostridioides difficile using a recombinant fusion protein vaccine containing flic and flid
AssigneeUniversity of South Florida
InventorXingmin Sun
Life of this patent
Estimating the term…
Abstract
A novel vaccine and methods of preventing and treating C. difficile infection in a patient is described. The vaccine is comprised of a fusion protein (denoted FliCD) comprised of the FliC and FliD from C. difficile and joined by a linker sequence. Administration of the vaccine, as well as anti-FliCD serum, has been shown to prevent C. difficile infection as well as treat existing infections.
Claims6
A method of preventing a C. difficile infection (CDI) in a patient in need thereof comprising:
- administering to the patient a therapeutically effective amount of a therapeutic agent, the therapeutic agent comprising a serum containing antibodies to at least one flagellin protein from C. difficile or a vaccine, the vaccine comprising
- a fusion protein comprising
- a portion of at least one flagellin protein (FliC) from C. difficile;
- and
- a portion of at least one cap protein (FliD) from C. difficile;
- and
- a pharmaceutically acceptable carrier;
- wherein the fusion protein has a sequence of SEQ ID NO:
- 7;
- wherein the administration of the serum or the vaccine to the patient prevents CDI.
7 more elements
A method of treating a C. difficile infection (CDI) in a patient in need thereof comprising:
- administering to the patient a therapeutically effective amount of a therapeutic agent selected from the group consisting of serum containing antibodies to at least one flagellin protein from C. difficile or a fusion protein composition;
- wherein the fusion protein composition comprises
- a fusion protein comprising
- a portion of at least one flagellin protein (FliC) from C. difficile;
- and
- a portion of at least one cap protein (FliD) from C. difficile;
- and
- a pharmaceutically acceptable carrier;
- wherein the fusion protein has a sequence of SEQ ID NO:
- 7;
- wherein the administration of the therapeutic agent to the patient reduces C. difficile toxin and/or C. difficile colonization in a tissue of the patient to treat the CDI.
8 more elements
Dependencies are inferred from the claim text.